All articles by Phillip Broadwith – Page 6
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
OpinionBehind enemy lines
When trade war breaks out, globalised industries ship out to dodge tariffs
-
BusinessCompany profile: Ellutia
Ellutia takes GC beyond the ‘box-in-the-lab’, with its customised chromatography
-
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
OpinionAre trade sanctions fair?
How much should markets be protected from cheaper imports? When does healthy competition become ‘dumping’?
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessBASF to buy Bayer seeds and herbicides
€5.9bn sale will help satisfy competition regulators’ worries over Bayer–Monsanto merger
-
NewsExplainer: What is cryo-electron microscopy
The science behind the 2017 Nobel prize in chemistry
-
OpinionShould individual companies be blamed for climate change?
Argument ignores consumers’ responsibility driven by our energy demands
-
BusinessBASF to buy Solvay’s polyamide business
€1.6bn deal covers 2400 employees at sites in Europe, Asia and the Americas
-
BusinessTeva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
-
BusinessEli Lilly to cut 3500 jobs
Company will close sites in US and China, and provide incentives for early retirement
-
-
OpinionAugmented intelligence
Robots will increasingly work alongside humans to solve complex problems
-
BusinessMallinckrodt settles US opioid lawsuit
Firm will pay $35m over allegations it failed to report suspicious orders of controlled substances
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project